Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Sep;26(9):1236-1241.
doi: 10.1016/j.cmi.2020.05.026. Epub 2020 Jun 2.

New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection

A Patel  1 , E Charani  2 , D Ariyanayagam  3 , A Abdulaal  1 , S J Denny  4 , N Mughal  5 , L S P Moore  5
Affiliations
Observational Study

New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection

A Patel et al. Clin Microbiol Infect. 2020 Sep.

Abstract

Objectives: We investigated the prevalence of anosmia and ageusia in adult patients with a laboratory-confirmed diagnosis of infection with severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2).

Methods: This was a retrospective observational analysis of patients infected with SARS-CoV-2 admitted to hospital or managed in the community and their household contacts across a London population during the period March 1st to April 1st, 2020. Symptomatology and duration were extracted from routinely collected clinical data and follow-up telephone consultations. Descriptive statistics were used.

Results: Of 386 patients, 141 (92 community patients, 49 discharged inpatients) were included for analysis; 77/141 (55%) reported anosmia and ageusia, nine reported only ageusia and three only anosmia. The median onset of anosmia in relation to onset of SARS-CoV-2 disease (COVID-19) symptoms (as defined by the Public Health England case definition) was 4 days (interquartile range (IQR) 5). Median duration of anosmia was 8 days (IQR 16). Median duration of COVID-19 symptoms in community patients was 10 days (IQR 8) versus 18 days (IQR 13.5) in admitted patients. As of April 1, 45 patients had ongoing COVID-19 symptoms and/or anosmia; 107/141 (76%) patients had household contacts, and of 185 non-tested household contacts 79 (43%) had COVID-19 symptoms with 46/79 (58%) reporting anosmia. Six household contacts had anosmia only.

Conclusions: Over half of the positive patients reported anosmia and ageusia, suggesting that these should be added to the case definition and used to guide self-isolation protocols. This adaptation may be integral to case findings in the absence of population-level testing. Until we have successful population-level vaccination coverage, these steps remain critical in the current and future waves of this pandemic.

Keywords: Ageusia; Anosmia; COVID-19; Coronavirus; Ear nose and throat [MeSH]; SARS-CoV-2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of participant selection for patients positive for severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) from a London community and a secondary-care population between March 1st and April 1st, 2020.
Fig. 2
Fig. 2
Onset and duration (in days) of anosmia in relation to COVID-19 symptoms in patients from a London community and a secondary-care population between March 1st and April 1st, 2020. Arrow indicates ongoing symptoms at the time of telephone consultations.
Fig. 3
Fig. 3
The presence of COVID-19 symptoms and anosmia in non-tested household contacts (n = 185) of patients from a London community and a secondary-care population tested positive for severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) between March 1st and April 1st, 2020.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Xydakis M.S., Dehgani-Mobaraki P., Holbrook E.H., Geisthoff U.W., Bauer C., Hautefort C. Smell and taste dysfunction in patients with COVID-19. Lancet Infect Dis. 2020 doi: 10.1016/S1473-3099(20)30293-0. - DOI - PMC - PubMed
    1. Mao L., Jin H., Wang M., Hu Y., Chen S., He Q. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020 doi: 10.1001/jamaneurol.2020.1127. - DOI - PMC - PubMed
    1. Giacomelli A., Pezzati L., Conti F., Bernacchia D., Siano M., Oreni L. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa330. - DOI - PMC - PubMed
    1. Hopkins C., Kumar N. British Rhinological Society and ENT-UK; London: 2020. Loss of sense of smell as marker of COVID-19 infection: joint statement from the.
    1. Lechien J.R., Chiesa-Estomba C.M., De Siati D.R., Horoi M., Le Bon S.D., Rodriguez A. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Oto-Rhino-Laryngology. 2020;2 doi: 10.1007/s00405-020-05965-1. - DOI - PMC - PubMed

Publication types